Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms (FREE)
By Joe Elia
Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 28, 2014 Category: Primary Care Source Type: news
Clinical effects of exposure to DPP-4 inhibitors as reported to the National Poison Data System - Russell JL, Casavant MJ, Spiller HA, Mercurio-Zappala M.
We examined all isolated exposures to DPP-4 inhibitors reported to t... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - February 15, 2014 Category: Global & Universal Tags: Poisoning Source Type: news
Januvia Lawsuits Move Forward, With Scheduling of Next Status...
The Firm is actively investigating potential Januvia lawsuit claims on behalf of individuals who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer due to their use of the Type 2...(PRWeb November 09, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11318046.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 10, 2013 Category: Pharmaceuticals Source Type: news
New York Attorney Now Accepting Januvia, Janumet, Byetta or...
Commack, New York law firm, Rudolph F.X. Migliore, P.C., is accepting cases from individuals who took the prescription medication Januvia, Janumet, Byetta or Victoza and later developed pancreatic...(PRWeb November 05, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11297852.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 5, 2013 Category: Pharmaceuticals Source Type: news
Januvia Lawsuit Claims Alleging Pancreatitis, Pancreatic Cancer Move...
The Firm is actively investigating potential Januvia lawsuit claims on behalf of individuals who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer as a result of taking the Type 2...(PRWeb October 30, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-lawyer/prweb11280123.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 1, 2013 Category: Pharmaceuticals Source Type: news
Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
(Institute for Quality and Efficiency in Health Care) New subgroup analyses showed that two studies on sitagliptin were also relevant for the fixed combination of sitagliptin/metformin. Hints of an added benefit can now be derived. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 9, 2013 Category: Global & Universal Source Type: news
The Numbers Behind The Job Cuts -- 5 Reasons Why Merck & Co. Was Forced To Wield The Axe
High Dependency On Januvia Franchise (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 3, 2013 Category: Pharmaceuticals Authors: Simon King Source Type: news
Novel Diabetes Drug Effective in Trial (CME/CE)
(MedPage Today) -- The investigational SGLT2 inhibitor empagliflozin lowers HbA1c as well as the widely used DPP-4 inhibitor sitagliptin (Januvia), and may work better than the incretin stimulator among patients with worse disease control, researchers found. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 10, 2013 Category: Endocrinology Source Type: news
Juvisync (Sitagliptin and Simvastatin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2013 Category: Drugs & Pharmacology Source Type: news
Januvia Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Order...
Januvia lawsuits pending in the newly-formed multidistrict litigation claim Merck & Co. failed to provide adequate warnings about the possible association between the use of Januvia and pancreatic...(PRWeb August 27, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11065983.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2013 Category: Pharmaceuticals Source Type: news
Januvia Lawsuits Being Investigated By Bernstein Liebhard LLP on...
A growing number of Januvia lawsuits allege Merck & Co. failed to provide adequate warnings to doctors and patients regarding an association between Januvia and pancreatic cancer and pancreatitis.(PRWeb August 11, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11015829.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 14, 2013 Category: Pharmaceuticals Source Type: news
Januvia-Pancreatic Cancer Lawsuit Investigation Announced by New York...
Januvia, a popular diabetes drug, has been linked to Pancreatic and Thyroid Cancer. A prominent New York Attorney has announced his firm is investigating Januvia-Pancreatic Cancer Lawsuits.(PRWeb July 30, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10972182.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 31, 2013 Category: Pharmaceuticals Source Type: news
Merck revenues miss mark as diabetes, arthritis drugs lag
(Reuters) - Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the
following statement regarding the conclusion of the European Medicines
Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)
review of GLP-1, or incretin-based, therapies, including sitagliptin.
Language:
English
Contact:
MerckMedia...
Source: Merck.com - Research and Development News - July 26, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Januvia Lawsuits Being Investigated by Bernstein Liebhard LLP, as...
The Firm is investigating Januvia lawsuits on behalf of patients who took Januvia and were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer.(PRWeb July 21, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10947930.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 22, 2013 Category: Pharmaceuticals Source Type: news
